Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897209 | 0.86 | GRM5 (0.46) | GRM5PKMTRPV1ALDH1A1 | |
| SCHEMBL2893212 | 0.85 | GRM5 (0.48) | GRM5ALDH1A1TSHR | |
| SCHEMBL2889851 | 0.81 | GRM5 (0.71) | GRM5PKM | |
| SCHEMBL2897207 | 0.81 | GRM5 (0.48) | GRM5PKMALDH1A1 | |
| SCHEMBL5482144 | 0.81 | GRM5 (0.71) | GRM5PKM | |
| SCHEMBL2897213 | 0.80 | GRM5 (0.47) | GRM5PKMHSD11B1TRPV1ALDH1A1 | |
| SCHEMBL2895532 | 0.75 | GRM5 (0.41) | GRM5ALDH1A1MET | |
| SCHEMBL2897839 | 0.74 | GRM5 (0.47) | GRM5PKMMAPK1ALDH1A1 | |
| SCHEMBL2900380 | 0.72 | GRM5 (0.46) | GRM5 | |
| SCHEMBL4051271 | 0.70 | GRM5 (0.48) | GRM5PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | GRM5 10/4885PKM 1183/4885HSD11B1 3330/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | GRM5 10/4885PKM 1245/4885HSD11B1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.